The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| POAI | -42.9% | -96.78% | -49.7% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +474% |
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -99.0% |
| Gross Profit | -$0.19M | -383.7% |
| Gross Margin | -6927.44% | -6913.7% |
| Market Cap | $7.97M | 88.5% |
| Market Cap / Employee | $0.33M | 0.0% |
| Employees | 24 | -29.4% |
| Net Income | -$1.98M | 37.8% |
| EBITDA | -$2.49M | 17.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.51M | -90.5% |
| Accounts Receivable | $0.02M | -94.1% |
| Inventory | 0 | -92.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.24M | -33.2% |
| Short Term Debt | $0.87M | 3.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -123.35% | -34.4% |
| Return On Invested Capital | -365.02% | -122.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.32M | -3.1% |
| Operating Free Cash Flow | -$3.32M | -3.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.67 | -26.88 | -92.62 | -4.82 | -561.85% |
| Price to Sales | 3.65 | 3.30 | 8.07 | 7.06 | 154.59% |
| Price to Tangible Book Value | 17.51 | 47.00 | -367.60 | -566.19 | -3501.10% |
| Enterprise Value to EBITDA | -1.92 | -3.29 | -4.57 | -3.68 | 401.73% |
| Return on Equity | -193.3% | -292.1% | -504.2% | -708.7% | 374.52% |
| Total Debt | $2.40M | $2.13M | $1.92M | $2.11M | -21.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
